Rapport Therapeutics Inc.
RAPP
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.47B
Close$
$0.88
97% downside
Current Fair Value
97% downsideOvervalued by 97% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.47 Billion |
|---|---|
| Enterprise Value | $1.41 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.86 |
| Beta | 1.03 |
| Outstanding Shares | 47,473,174 |
Return
| Return on Equity | -32.43% |
|---|---|
| Return on Assets | -29.88% |
| Return on Invested Capital | -35.39% |
Valuation & Multiples
| P/E Ratio | -10.08 |
|---|---|
| PEG | -9.02 |
| Price to Sales | - |
| Price to Book Ratio | 3.7 |
| Enterprise Value to Revenue | 70.62 |
| Enterprise Value to EBIT | -9.27 |
| Enterprise Value to Net Income | -11 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.96
Average shareholder expectationRevenue Estimate
$2.22 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.20
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 124.14% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▼ 109.06% |
|---|---|
| Total Invested | $24,528▼ 100.00% |
| Investors Holding | 4▼ 162.00% |
ESG Score
No data